Hotbed/Location
Filter News
Found 736,779 articles
-
Media Alert:Bayer is recalling two lots of hydraSense® Baby Nasal Care Easydose® due to potential contamination
4/18/2024
Bayer is recalling two lots of hydraSense® Baby Nasal Care Easydose® due to a potential contamination.
-
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
4/18/2024
Nexcella today announced that it is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
-
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
4/18/2024
Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows, chickens and one person in Texas.
-
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
4/18/2024
RenovoRx, Inc. announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC that the Company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550.
-
GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging
4/18/2024
GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence, advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health.
-
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations
4/18/2024
Kindeva Drug Delivery, a global leader in drug-device combination products, announced that Denis Johnson has joined the company as its new Chief Operating Officer.
-
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
4/18/2024
Renovaro Inc., a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board.
-
Novel cell therapy treatments offer promise to immune-compromised children
4/18/2024
In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from virus-specific T-cells can effectively treat immunocompromised pediatric patients, far surpassing the current standard of care, according to new research published in Nature Communications.
-
NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
4/18/2024
In a proof-of-concept study, researchers at the National Institutes of Health have developed an artificial intelligence tool that uses data from individual cells inside tumors to predict whether a person's cancer will respond to a specific drug.
-
Agitated Solutions Receives Health Canada License for Orbis Microbubble Generator to Streamline Cardiac Bubble Studies
4/18/2024
Agitated Solutions, Incorporated announced that it has been issued a Medical Device Establishment License from Health Canada for its innovative Orbis™ Microbubble Generator that simplifies and streamlines the process of saline agitation and delivery for cardiac bubble studies.
-
Precision Optics Announces Receipt of $720,000 Follow-On Production Order from Top Tier Defense/Aerospace Customer for New Optical Application
4/18/2024
Precision Optics Corporation, Inc. announced it has received a $720,000 follow on production order from a top tier defense/aerospace company addressing a commercial application that leverages the Company's proprietary manufacturing technology developed for high precision micro-optics systems.
-
Genetic Technologies Announces $2 Million Registered Direct Offering
4/18/2024
Genetic Technologies Limited announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares, each representing thirty ordinary shares of the Company, at a purchase price of $2.00 per ADS.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
4/18/2024
NRx Pharmaceuticals, Inc. announced that has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550 and has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter.
-
Computational Biology Pioneer Katie Pollard Elected as AAAS Fellow
4/18/2024
The American Association for the Advancement of Science, one of the world's largest general scientific societies, has elected Gladstone Senior Investigator Katie Pollard, PhD, into its new class of AAAS Fellows, a lifetime honor within the scientific community.
-
Soligenix Announces Pricing of $4.75 Million Public Offering
4/18/2024
Soligenix, Inc. announced the pricing of its public offering of 11,875,000 shares of common stock and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses.
-
Initial Therapeutics Names Peter DiLaura as CEO
4/18/2024
Initial Therapeutics Inc. has appointed Peter DiLaura as President and Chief Executive Officer and a member of the company's Board of Directors, effective immediately.
-
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
4/18/2024
Chemomab Therapeutics Ltd. today announced the publication of a new study that further confirms the key role of its novel soluble protein target CCL24 in systemic sclerosis (SSc).
-
Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)
4/18/2024
The International Cartilage Regeneration & Joint Preservation Society has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research, its new President-Elect.
-
Redwood Scientific Technologies Inc.today announced a strategic shift in its product development priorities
4/18/2024
Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities.
-
Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer
4/18/2024
Partner Therapeutics, Inc. announced publication of a comprehensive review by Dougan et al. in Cancers summarizing the mechanistic rationale and pre-clinical and clinical data regarding the use of Leukine to manage gastrointestinal immune-related adverse events for patients taking immune checkpoint inhibitors for the treatment of cancer.